Antifibrotic Effect of Pirfenidone on Human Pterygium Fibroblasts

REFERENCES

• Kheirkhah A, Hashemi H, Adelpour M, Nikdel M, Rajabi MB, Behrouz MJ. Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. Ophthalmology 2012;119:227–232
   PubMedGoogle Scholar
• Kheirkhah A, Adelpour M, Nikdel M, Ghaffari R, Ghassemi H, Hashemi H. Evaluation of conjunctival graft thickness after pterygium surgery by anterior segment optical coherence tomography. Curr Eye Res 2011;36:782–786
   PubMed Web of Science ®Google Scholar
• Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Di Girolamo N. Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol 2011;178:817–827
   PubMed Web of Science ®Google Scholar
• Kwok LS, Coroneo MT. A model for pterygium formation. Cornea 1994;13:219–224
   PubMed Web of Science ®Google Scholar
• Jaros PA, DeLuise VP. Pingueculae and pterygia. Surv Ophthalmol 1988;33:41–49
   PubMed Web of Science ®Google Scholar
• Singh G, Wilson MR, Foster CS. Mitomycin eye drops as treatment for pterygium. Ophthalmology 1988;95:813–821
   PubMed Web of Science ®Google Scholar
• MacKenzie FD, Hirst LW, Kynaston B, Bain C. Recurrence rate and complications after beta irradiation for pterygia. Ophthalmology 1991;98:1776–1780; discussion 81
   PubMed Web of Science ®Google Scholar
• Kleis W, Pico G. Thio-TEPA therapy to prevent postoperative pterygium occurrence and neovascularization. Am J Ophthalmol 1973;76:371–373
   PubMedGoogle Scholar
• Tan D. Conjunctival grafting for ocular surface disease. Curr Opin Ophthalmol 1999;10:277–281
   PubMedGoogle Scholar
• Ti SE, Tseng SC. Management of primary and recurrent pterygium using amniotic membrane transplantation. Curr Opin Ophthalmol 2002;13:204–212
   PubMedGoogle Scholar
• Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 1997;104:974–985
   PubMed Web of Science ®Google Scholar
• Lewallen S. A randomized trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989;96:1612–1614
   PubMedGoogle Scholar
• Rao SK, Lekha T, Sitalakshmi G, Padmanabhan P. Conjunctival autograft for pterygium surgery: how well does it prevent recurrence? Ophthalmic Surg Lasers 1997;28:875–877
   PubMedGoogle Scholar
• Chen PP, Ariyasu RG, Kaza V, LaBree LD, McDonnell PJ. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995;120:151–160
   PubMed Web of Science ®Google Scholar
• Luanratanakorn P, Ratanapakorn T, Suwan-Apichon O, Chuck RS. Randomised controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision. Br J Ophthalmol 2006;90:1476–1480
   PubMed Web of Science ®Google Scholar
• Karabatsas CH, Marsh GW, Cook AM, Cook SD. Different therapeutic approaches and outcome in the treatment of pterygium. Eur J Ophthalmol 1998;8:148–152
   PubMedGoogle Scholar
• Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol 1997;115:1235–1240
   PubMed Web of Science ®Google Scholar
• Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007;18:308–313
   PubMed Web of Science ®Google Scholar
• Menghini M, Watson SL, Bosch MM. Corneal melting two weeks after pterygium excision with topical mitomycin C: successfully treated with lamellar keratoplasty and amnion membrane transplantation. Case Report Ophthalmol 2012;3:24–29
   PubMedGoogle Scholar
• Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008 20;590:400–408
   Google Scholar
• Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004;24:57–65
   PubMed Web of Science ®Google Scholar
• Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci 2003;75:169–180
   PubMed Web of Science ®Google Scholar
• Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004;36:744–751
   PubMedGoogle Scholar
• Tada S, Nakamuta M, Enjoji M, Sugimoto R, Iwamoto H, Kato M, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 2001;28:522–527
   PubMed Web of Science ®Google Scholar
• Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, Jou I, et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 2010;51:3061–3066
   PubMedGoogle Scholar
• Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon’s fibroblasts in vitro. Invest Ophthalmol Vis Sci 2009;50:3763–3770
   PubMed Web of Science ®Google Scholar
• Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology 2013;120:201–208
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040–1047
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061–1069
   PubMed Web of Science ®Google Scholar
• Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002;37:584–591
   PubMedGoogle Scholar
• Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001;14:453–460
   PubMed Web of Science ®Google Scholar
• Seong GJ, Park C, Kim CY, Hong YJ, So HS, Kim SD, et al. Mitomycin-C induces the apoptosis of human Tenon’s capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Investig Ophthalmol Vis Sci 2005;46:3545–3552
   PubMedGoogle Scholar